StockData
SCYNEXIS Inc logo

SCYNEXIS Inc (SCYX) stock

SCYXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 13/3071% below fair value
$2.91−0.30 (-9.35%)

Close on Nov 16, 2026Market cap $28.95MP/E –Yield –

Scynexis ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

Scynexis's ebitda for the twelve months ending Dec 31, 2024 was -$37.12M, down 150.7% year over year. For fiscal 2024 it was -$37.12M, down 150.7% from the year before. The highest annual figure on record is $73.25M in fiscal 2023.

Annual ebitda

PeriodPeriod endValueChange
FY2024Dec 31, 2024-$37.12M-150.7%
FY2023Dec 31, 2023$73.25M–
FY2022Dec 31, 2022-$85.15M–
FY2021Dec 31, 2021-$60.46M–
FY2020Dec 31, 2020-$51.04M–

Quarterly ebitda

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2024Dec 31, 2024-$8.05M–
Q3 FY2024Sep 30, 2024-$10.32M–
Q2 FY2024Jun 30, 2024-$9.24M-107.9%
Q1 FY2024Mar 31, 2024-$9.51M–
Q4 FY2023Dec 31, 2023-$22.94M–
Q3 FY2023Sep 30, 2023-$9.95M–
Q2 FY2023Jun 30, 2023$116.67M–
Q1 FY2023Mar 31, 2023-$10.53M–
Q4 FY2022Dec 31, 2022-$22.33M–
Q3 FY2022Sep 30, 2022-$21.65M–
Q2 FY2022Jun 30, 2022-$21.59M–
Q1 FY2022Mar 31, 2022-$19.58M–
Q4 FY2021Dec 31, 2021-$22.05M–
Q3 FY2021Sep 30, 2021-$19.39M–
Q2 FY2021Jun 30, 2021-$17.45M–
Q1 FY2021Mar 31, 2021-$1.57M–

More Scynexis figures

See a number that looks wrong?